MERIDIAN BIOSCIENCE, INC. (NASDAQ:VIVO) Files An 8-K Results of Operations and Financial Condition
Item 2.02.Results of Operation and Financial Condition.

On October 19, 2017, the Company issued a press release commenting on preliminary operating results for the fiscal year ended September 30, 2017.A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information contained herein shall not be deemed "filed" for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

MERIDIAN BIOSCIENCE INC Exhibit
EX-99.1 2 form8k101917_ex99.htm PRESS RELEASE OF THE COMPANY DATED OCTOBER 19,…
To view the full exhibit click here

About MERIDIAN BIOSCIENCE, INC. (NASDAQ:VIVO)

Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.